Imago BioSciences, Inc.

Practice Area: 
Stock Symbol: 
Case Status: 

Ademi LLP is investigating Imago (Nasdaq: IMGO) for possible breaches of fiduciary duty and other violations of law in its transaction with Merck.

Ademi LLP alleges Imago’s financial outlook and prospects are excellent and yet Imago holders will receive only $36.00 per share in cash for an approximate total equity value of $1.35 billion. The transaction agreement unreasonably limits competing bids for Imago by imposing a significant penalty if Imago accepts a superior bid. Imago insiders will receive substantial benefits as part of change of control arrangements.

We are investigating the conduct of Imago’s board of directors, and whether they are (i) fulfilling their fiduciary duties to all shareholders, and (ii) obtaining a fair and reasonable price for Imago.